Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
rubber dildos.
Popular Articles

Health Insurance Premiums For Families Topped $12,000 A Year In 2008
The cost of insuring a family of four with an employer-sponsored health plan in the United States averaged $12,298 in 2008, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
diet pills
Coalition For Quality & Patient Safety Of Chicagoland PSO Taps ECRI Institute PSO For Support
ECRI Institute Patient Safety Organization (PSO) is pleased to announce an agreement with the Coalition for Quality & Patient Safety (CQPS) of Chicagoland PSO to provide patient safety data collection, reporting, and analysis. The Chicagoland PSO focuses on local experience, patterns, trends, and patient safety initiatives specific to Chicago and the surrounding counties. CQPS will coordinate its PSO and other patient safety efforts with other Illinois-based hospital and primary care associations, the Illinois Department of Public Health, consumers and consumer advocates, other patient safety and quality improvement stakeholders, and existing patient safety collaboratives across the state.
News of the day
Blood Test Shows Statistically Significant Association With Alzheimer's Disease (AD), May Predict Conversion Of Mild Cognitive Impairment To AD
Dr. Zsuzsanna Nagy of the University of Birmingham presented data from a clinical study, funded by Cytox Limited, demonstrating that a simple blood-based biomarker discriminated between patients with Alzheimer"s disease (AD) and control subjects. The findings were statistically highly significant, and the test discriminated between the two groups with 80% sensitivity and 80% specificity. The results also showed that 40% of the mild cognitive impairment (MCI) patients tested had the same test results as AD patients. Follow up study of MCI patients enrolled in an earlier study found that the test allowed early identification of those MCI patients who later developed dementia. The results were presented at the 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009), held in Vienna, Austria.
Public Health

PROSTVAC(TM) Data Presented At The ASCO Meeting Demonstrates The Potential For Significant Increases In Life Expectancy In Late-Stage Prostate Cancer

Detailed data from a randomized Phase 2 study with PROSTVAC(TM) were presented Saturday at the ASCO Annual Meeting in Orlando. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School, and the Dana-Farber Cancer Institute who is also the principal investigator of the study. The more detailed analysis supports the headline data that were reported in October 2008. In the Phase 2 prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer, patients in the PROSTVAC(TM) group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is 0.56 (95% CI 0.37-0.85). The statistical significance in the final data set is (p=0.006). There were no major clinically meaningful imbalances in baseline characteristics in the PROSTVAC(TM) and control vector treated arms. PROSTVAC(TM) immunotherapy was well tolerated, with some patients having injection site reactions (40-60%), and systemic symptoms of fatigue, fevers, and chills (10-30%) reported. PROSTVAC(TM) is an "off-the-shelf" viral vector-based immunotherapy, utilizing pox virus vectors that express PSA and three T cell costimulatory molecules are administered subcutaneously. Philip Kantoff MD, Professor of Medicine, Harvard Medical School, the principal investigator of the study, said: "There are few available treatments for advanced prostate cancer. To see this extent of improvement in overall survival is very encouraging. These phase II data with PROSTVAC(TM) warrant confirmation with a phase III study and when confirmed this product has the potential to fulfil an unmet medical need for these patients." Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are delighted that the data presented at the ASCO Annual Meeting confirms the excellent headline data with our prostate cancer vaccine candidate, PROSTVAC(TM), ready to start Phase 3 in 2010." About PROSTVAC(TM) PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical development that has the potential to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks prostate cancer cells. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects. In contrast, PROSTVAC(TM) has the potential to extend survival with improved quality of life. PROSTVAC(TM) is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement with Bavarian Nordic"s U.S.-based subsidiary, BN ImmunoTherapeutics. In clinical trials to date PROSTVAC(TM) and related PSA containing poxviral vaccines have been investigated and optimised in more than 500 patients for 10 years. Forward-looking statements This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. About Bavarian Nordic Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company"s business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic"s proprietary and patented technology MVA-BN(R) is one of the world"s safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company"s third-generation smallpox vaccine, IMVAMUNE(R). Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA. Bavarian Nordic A/S


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009